ASP 8273

Drug Profile

ASP 8273

Alternative Names: ASP8273

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Antineoplastics; Piperazines; Piperidines; Pyrazines; Pyrrolidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Solid tumours in USA (PO) (NCT02674555)
  • 21 Jan 2016 Astellas plans a phase I pharmacokinetic trial for Solid tumours in USA (NCT02674555)
  • 21 Dec 2015 Phase-III clinical trials in Non-small cell lung cancer (First-line therapy, Late-stage disease) in Hungary (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top